Two drug-delivery technologies developed by the French company Flamel Technologies will play starring roles in a new deal the company has reached with the Spanish company Digna Biotech. Digna will use Flamel's Medusa and Micropump technologies in three initial Digna products.
They are: P144 (Disitertide), a Transforming Growth Factor beta-1 (TGF-beta1) treatment of systemic sclerosis or scleroderma; P17, another TGF-beta1 inhibitor for treatment cirrhosis; and Methylthiadenosine (MTA) for possible treatment of multiple sclerosis.
"By applying Flamel's drug delivery expertise, we expect to improve the applicability of these promising candidates to the indications we are seeking to address," Pablo Ortiz Digna's CEO, said in a statement. "We also expect to fuel this collaboration with further innovative molecules in Digna's pipeline as we develop further preclinical development in these programs."
Flamel's Medusa and Micropump technologies address issues such as poor solubility, aggregation and instability for chemical and biological drugs, the company says.